Drug class
Selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; antineoplastic
Mechanism of action
Inhibits VEGFR1, VEGFR2 and VEGFR3 kinase activity, suppressing angiogenesis and tumour-associated vascular signalling.
General use cases
- Treatment of adults with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy and, if RAS wild-type, anti-EGFR therapy, under the applicable US product indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
